Description
Title: Immune checkpoint inhibitors for non-small cell lung cancer: a practical guide
Abstract: Lung cancer treatment has been revolutionized by immunotherapy using immune checkpoint inhibitors (ICIs). Blockers of PD-1 and PD-L1 have been shown to increase overall survival in non-small cell lung cancer that has spread to other organs. Three to five years of survival have been achieved in specific patients. For the treatment of lung cancer, nivolumab, brolizumab, and atezolizumab are approved. Real-world observations demonstrate that the outcomes are comparable to those obtained in clinical trials. Age, sex, histology, and the patient’s performance status all affect how well ICIs work. The presence of brain metastases has no effect on how well ICIs work. Immune-related adverse events are noticed, but the ICIs therapy is safe and well tolerated. Glucocorticoids are typically curative, though pneumonitis can be a serious and fatal complication. The detection of PD-L1 expression on cancer cells is used to properly select patients for ICIs treatment. The so-called “hot” tumors, which exhibit high levels of PD-L1 expression and extensive infiltration by cytotoxic cells, appear to respond to therapy better than the “cold” tumors.
Keywords: lung cancer, PD-1, PD-L1, immunotherapy, adverse events, immunoscoring
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Advances in Respiratory Medicine
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.